<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00214253</url>
  </required_header>
  <id_info>
    <org_study_id>2001-529</org_study_id>
    <nct_id>NCT00214253</nct_id>
  </id_info>
  <brief_title>Islet Transplantation in Type 1 Diabetic Patients</brief_title>
  <official_title>Islet Transplantation in Type 1 Diabetic Patients Using a Steroid-free Immunosuppression Protocol and Thiazolidinedione Insulin Sensitizers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <brief_summary>
    <textblock>
      Our hypothesis is that a successful clinical islet transplant program can be established at
      the University of Wisconsin using a steroid -free, sirolimus- and low dose tacrolimus - based
      immunosuppressive drug regimen (Edmonton protocol). We intend to answer the following
      research questions: 1) will treatment of islet transplant recipients with thiazolidinediones
      (i.e. pioglitazone) enhance post-transplant islet function and reduce the number of islets
      necessary to achieve adequate metabolic control? 2) which type 1 diabetic patients are
      optimal candidates for islet transplantation (i.e. islet transplant alone or islet after
      kidney transplantation)? 3) Can cadaver donor pancreases, which are ordinarily discarded and
      not used for pancreas transplantation be used for islet transplantation?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of islets necessary to achieve adequate metabolic control</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>post-transplant islet function</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suitability of cadaver donor pancreases for islet transplantation</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thiazolidinedione therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiazolidinedione</intervention_name>
    <description>Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  16 Type I insulin-dependent diabetic subjects ages 18-60,(8 who have received a prior
             kidney or liver transplant and have stable renal function, and 8 who have labile
             glucose regulation and who have failed a trial of intensive exogenous insulin therapy
             and who have preserved native renal function)

        Exclusion Criteria:

          -  untreated proliferative diabetic retinopathy;

          -  HgbA1C &gt;12%; creatinine clearance &lt; 80 ml/minute or macroalbuminuria &gt; 0.3 gm/24 hrs;

          -  presence of panel reactive antibodies &gt;20%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Odorico, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2,4-thiazolidinedione</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

